Clinical Trial Update: Azacitidine in Combination With Venetoclax Treatment for MRD Positive Post Allo-HSCT AML/MDS Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating azacitidine in combination with venetoclax for MRD-positive post allogeneic stem cell transplant AML/MDS patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Venetoclax (venetoclax)

Snippet

Sponsor: First Affiliated Hospital of Zhejiang University | Conditions: Hematologic Malignancy, Stem Cell Transplant Complications | Phase 2 | Status: UNKNOWN